A Randomised Controlled Trial Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere’s Disease with Good Hearing

• Published in: Indian journal of otolaryngology, and head, and neck surgery Vol. 76; no. 5; pp. 3793 - 3799
• Main Authors: Alex, Anu, Mammen, Manju Deena, Lepcha, Anjali, Reka, K., Augustine, Ann Mary, Philip, Ajay
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.10.2024; Springer Nature B.V
• Subjects: Head and Neck Surgery; Medicine; Medicine & Public Health; Original Article; Otorhinolaryngology; Tinnitus; Vertigo; Intratympanic Gentamicin; Intratympanic Methyl Prednisolone; Meniere’s disease; Serviceable hearing
• ISSN: 2231-3796; 0973-7707
• DOI: 10.1007/s12070-024-04749-x

A randomized prospective parallel group trial was done to compare the efficacy of intratympanic low dose gentamicin with methylprednisolone in treating intractable unilateral Meniere’s disease with serviceable hearing. Study Design: Randomised prospective parallel group trial. Setting: Tertiary care centre in South India. Subjects and methods: Forty patients with unilateral Meniere’s disease and serviceable hearing with vertigo following 6 months of conservative therapy were enrolled between November 2018 and March 2020. Twenty patients were administered with one dose of intratympanic Gentamicin (40 mg/ml) and the other half were given intratympanic Methylprednisolone (40 mg/ml, 4 injections given on alternate days). Pure tone audiogram, speech discrimination score, number of vertigo episodes, dizziness handicap inventory, tinnitus handicap inventory and functional scores were compared before treatment, 3 months later and up to 24 months. There was no significant difference between the two treatments with regard to short term as well as long term DHI scores, THI scores, Functional level score and average pure tone audiogram of patients. In patients with unilateral Meniere’s disease who have good hearing, one dose of Gentamicin had equivalent effect to that of four doses of Methylprednisolone in vertigo and tinnitus control, hearing preservation and quality of life.